Welcome to our dedicated page for INCYTE SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
INCYTE CORP chief medical officer Steven H. Stein reported an automatic share withholding to cover taxes tied to equity compensation. On this Form 4, 2,177 shares of common stock were withheld at an indicated value of $116.86 per share to satisfy tax withholding obligations when restricted stock units or earned performance shares settled.
After this tax-withholding disposition, Stein directly holds 76,150 shares of common stock. Footnote disclosure adds that his position also includes 73,591 shares of common stock underlying previously reported restricted stock units and earned performance shares that have not yet vested. This event reflects compensation-related tax treatment rather than an open-market sale.
Incyte Corporation has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, for an upfront payment of $1.25 billion. Star Therapeutics may receive up to an additional $750 million in sales milestone payments. The deal adds VGA039, an investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s hematology portfolio and late-stage pipeline. VGA039 is being developed as a once-monthly subcutaneous prophylactic therapy and has received multiple U.S. FDA designations, including Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease. Incyte expects to record the transaction as a one-time R&D expense in its third-quarter and full-year 2026 GAAP and non-GAAP results.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP reported that investment entities affiliated with Baker Bros. Advisors received a grant of 400 shares of Common Stock as director compensation in lieu of a $40,500 quarterly retainer. Following this award, Baker Bros.–related funds report indirect holdings of up to 28,205,760 Incyte shares, while Julian and Felix Baker also hold additional direct and partnership stakes.
Clancy Paul J reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director Paul J. Clancy received 252 shares of common stock as a grant under the company’s Amended and Restated 2010 Stock Incentive Plan. The award was issued in lieu of quarterly director retainer fees pursuant to an election intended to comply with Rule 10b5-1, and the restricted shares are fully vested.
Following this grant, Clancy directly holds 25,635 shares of common stock, which includes 1,642 shares underlying previously reported restricted stock units that have not yet vested. This filing reflects routine equity compensation rather than an open-market purchase or sale.
HARRIGAN EDMUND reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director Edmund Harrigan received 255 shares of common stock as a fully vested restricted stock grant. The shares were issued under Incyte’s Amended and Restated 2010 Stock Incentive Plan in lieu of his quarterly director retainer fees, pursuant to an election intended to comply with Rule 10b5-1. After this grant, he beneficially owns 23,019 shares of common stock, which includes 1,642 shares issuable from previously reported restricted stock units that have not yet vested.
Incyte Corporation has reached a settlement with the Centers for Medicare & Medicaid Services regarding how Medicaid rebate rules apply to Opzelura (ruxolitinib) cream. CMS will not treat Opzelura as a line extension of Jakafi for rebate purposes, and Incyte has withdrawn its related lawsuit. The company expects to record a one-time, non-cash benefit of approximately $246 million in the quarter ending June 30, 2026, reflecting reversal of accruals previously recorded through March 31, 2026. Incyte will stop accruing for potential line extension liabilities on Opzelura and anticipates better gross-to-net performance for the product going forward. The company plans to update its financial guidance to reflect the settlement in its next earnings release.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director representative entities report equity awards tied to Julian C. Baker’s board service. On June 8, 2026, Baker-related fund entities were granted 1,642 restricted stock units and 6,111 non-qualified stock options linked to Incyte common stock as director compensation.
The stock options carry a $100.64 strike price and expire on June 7, 2036. Both the RSUs and options vest on the earlier of June 8, 2027, the next Incyte annual stockholder meeting, or a change in control, subject to Julian C. Baker’s continued board service. The filing states Baker Bros. Advisors LP has voting and dispositive power over these awards, while Julian C. Baker and Felix J. Baker are described as having only indirect pecuniary interests through their fund and general partner ownership.
INCYTE CORP director Edmund Harrigan received new equity awards as part of his compensation. He was granted 1,642 restricted stock units that settle one-for-one into common shares, bringing his direct common stock holdings to 22,764 shares after the award.
He also received a non-qualified stock option covering 6,111 shares of common stock at an exercise price of $100.64 per share. Both the RSUs and the option vest in full on the first anniversary of the grant date, or earlier upon the next regular annual stockholder meeting or a change of control, with the option expiring on June 7, 2036.
INCYTE CORP director Paul J. Clancy received new equity awards as part of his compensation. He was granted 1,642 shares of common stock in the form of restricted stock units, which vest in full on the first anniversary of the grant date, or earlier if the next regular annual stockholder meeting occurs or there is a change of control. He also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, with the same vesting schedule. Following these awards, he holds 25,383 shares of common stock directly.
Incyte Corp director Jacqualyn A. Fouse received new equity awards consisting of restricted stock units and stock options. She was granted 1,642 RSUs that vest in full on the first anniversary of the grant date, or earlier if the next regular annual stockholder meeting occurs first, or upon a change of control as defined in the RSU plan. The RSUs settle into common stock on a one-for-one basis. She also received a non-qualified stock option for 6,111 shares of common stock at an exercise price of $100.64 per share, vesting on the same schedule and expiring in 2036. Following these awards, she directly holds 20,968 shares of common stock.